Browsing by Subject "Nanoparticles"
Now showing items 1-6 of 6
-
Design and formulation of nano-sized spray dried efavirenz-part I: influence of formulation parameters
(Springer Nature Switzerland AG., 2012-10-25)Efavirenz (EFV) is one of the first-line antiretroviral drugs recommended by the World Health Organisation for treating HIV. It is a hydrophobic drug that suffers from low aqueous solubility (4 μg/mL), which leads to a ... -
Effects of protein binding on the biodistribution of PEGylated PLGA nanoparticles post oral administration
(Elsevier B.V., 2012-03-15)The surface of nanoparticles is often functionalised with polymeric surfactants, in order to increase systemic circulation time. This has been investigated mainly for intravenously administered nanoparticles. This study ... -
Facile biosynthesis of Ag–ZnO nanocomposites using Launaea cornuta leaf extract and their antimicrobial activity
(NM-AIST, 2013-11-14)The quest to synthesize safe, non-hazardous Ag–ZnO nanoomposites (NCs) with improved physical and chemical prop- erties has necessitated green synthesis approaches. In this research, Launaea cornuta leaf extract was ... -
Facile biosynthesis of Ag–ZnO nanocomposites using Launaea cornuta leaf extract and their antimicrobial activity
(Springer Nature, 2023-11-17)The quest to synthesize safe, non-hazardous Ag–ZnO nanoomposites (NCs) with improved physical and chemical properties has necessitated green synthesis approaches. In this research, Launaea cornuta leaf extract was proposed ... -
In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems
(Elsevier Inc., 2010-10)The remarkable physicochemical properties of particles in the nanometer range have been proven to address many challenges in the field of science. However, the possible toxic effects of these particles have raised some ... -
Nanoencapsulation of water-soluble drug, lamivudine, using a double emulsion spray-drying technique for improving HIV treatment
(Springer Nature Switzerland AG., 2013-10-22)Current treatments available for human immunodeficiency virus, namely antiretrovirals, do not completely eradicate the virus from the body, leading to life-time commitment. Many antiretrovirals suffer drawbacks from ...
